The FDA accepted the GTx-104 application on August 22, 2025, with an April 23, 2026 target date. Warrants from the September 2023 private placement, at $3.003 each, expire on the earlier of the 60th day after acceptance or September 25, 2028.
Grace Therapeutics expects about $13.8 million in net proceeds from a private placement at $3.395 a share, with TD Securities (USA) LLC as placement agent. The same day, its Phase 3 safety trial of GTx-104 was reported, and the company's own release says the trial was not powered to show efficacy.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $13.8 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Grace Therapeutics
Has Grace Therapeutics raised money recently?
Our latest story on this, dated Aug 27, 2025: "Grace Therapeutics NDA acceptance opens window on up to $7.6 million in warrants". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Grace Therapeutics?
Grace Therapeutics, Inc. trades under the ticker GRCE on NASDAQ.
Where is Grace Therapeutics listed?
Grace Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Grace Therapeutics?
The SEC Central Index Key (CIK) for Grace Therapeutics, Inc. is 1444192. Its filings are on SEC EDGAR.
How many shares does Grace Therapeutics have outstanding?
21,035,930 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13.
Which country or territory is Grace Therapeutics listed under?
Our directory records Grace Therapeutics, Inc. under United States.
What does Grace Therapeutics do?
Our directory classifies Grace Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Grace Therapeutics?
The ISIN recorded for Grace Therapeutics, Inc. is US00439U1043.
Does aibio.space cover Grace Therapeutics?
aibio.space lists Grace Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Grace Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
Is Grace Therapeutics profitable?
Grace Therapeutics, Inc. reported a net loss of $7.8 million for the fiscal year ended Mar 31, 2026, and used $8.9 million of cash in operations, per its annual report to the SEC.
How much does Grace Therapeutics spend on research and development?
$2.4 million in the fiscal year ended Mar 31, 2026, per its annual report.
How much cash does Grace Therapeutics have?
$13.8 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest Grace Therapeutics (GRCE) stock news?
Our latest story on Grace Therapeutics, dated Aug 27, 2025: "Grace Therapeutics NDA acceptance opens window on up to $7.6 million in warrants". The FDA accepted the GTx-104 application on August 22, 2025, with an April 23, 2026 target date. Warrants from the September 2023 private placement, at $3.003 each, expire on the earlier of the 60th day after acceptance or September 25, 2028. Source.
What is Grace Therapeutics's market cap?
We do not publish live share prices. In its annual report, Grace Therapeutics, Inc. put the market value of shares held by non-affiliates (public float) at $35.1 million as of Sep 30, 2025.
Investor discussion: Grace Therapeutics
Members talk about Grace Therapeutics (GRCE). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Grace Therapeutics, newest first. Each line links the filing it comes from.
Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Financings
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Financings
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Financings
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:GRCE on TradingView.
SEC filings and registration
SEC name
Grace Therapeutics, Inc.
CIK
1444192
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
GRCE (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
March 31
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
103 CARNEGIE CENTER, PRINCETON, NJ, 08540
Phone
609-322-1602
Shares outstanding
21,035,930 as of 2026-08-11 (10-Q filed 2026-08-13)
Former names
Acasti Pharma Inc.
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Grace Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker GRCE, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio